Sanofi Entered into an Agreement with Janssen to Develop and Commercialize Vaccine Candidate for Extraintestinal Pathogenic E. Coli
Shots:
- Janssen will receive $175M up front & is eligible to obtain development & commercial milestones along with royalties and sales milestones in the rest of the world. Both parties will have a profit-share arrangement in the US, the UK & the EU (Germany, Italy, Spain & France)
- The companies will co-fund the costs of present & future research and development activities. The agreement will combine Janssen’s robust science behind first-in-class products with Sanofi’s worldwide manufacturing footprint and recognized expertise in launching innovative vaccines
- The 9-valent extraintestinal pathogenic E. coli vaccine (ExPEC9V) is currently being evaluated in the P-III trial (E.mbrace) trial against PBO in the prevention of invasive E. coli disease caused by ExPEC9V O-serotypes
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi and Regeneron Report P-III Trial (PRIME) and (PRIME2) Results of Dupixent (dupilumab) for the Treatment of Prurigo Nodularis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
